Possible Quad Pricing Raises Congressional Eyebrows
By Mari Serebrov
Wednesday, August 15, 2012
With the PDUFA date for Gilead Sciences Inc.'s Quad less than a fortnight off, the company is coming under congressional pressure to reduce the expected price of what is likely to be the next big HIV therapy.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.